AKBA Insider Trading Activity and SEC Form 4 Filings
AKBA insider trading summary
Over the past 12 months, insiders at Akebia Therapeutics, Inc. (AKBA) reported 16 sales worth $963K by 6 insiders and 1 open-market purchase worth $87K by 1 insider on SEC Form 4. Net insider selling was $876K.
Latest AKBA insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Jun 29, 2026 | Erik Ostrowski | SVP, CFO, CBO & Treasurer | Sell | $62K (56,019 @ $1.11) |
| Mar 4, 2026 | John P. Butler | CEO and President | Buy | $87K (69,270 @ $1.25) |
| Feb 2, 2026 | Steven Keith Burke | SVP, Chief Medical Officer | Sell | $30K (21,582 @ $1.39) |
| Feb 2, 2026 | John P. Butler | CEO and President | Sell | $116K (83,689 @ $1.39) |
| Feb 2, 2026 | Carolyn M. Rucci | SVP, Chief Legal Officer | Sell | $23K (16,846 @ $1.39) |
| Feb 2, 2026 | Carolyn M. Rucci | SVP, Chief Legal Officer | Sell | $35K (25,382 @ $1.39) |
| Feb 2, 2026 | John P. Butler | CEO and President | Sell | $65K (46,660 @ $1.39) |
| Feb 2, 2026 | John P. Butler | CEO and President | Sell | $134K (96,065 @ $1.39) |
| Feb 2, 2026 | John P. Butler | CEO and President | Sell | $160K (114,891 @ $1.39) |
| Feb 2, 2026 | Erik Ostrowski | SVP, CFO, CBO & Treasurer | Sell | $49K (34,951 @ $1.39) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.